[go: up one dir, main page]

GB202306990D0 - Cannabinoid-based formulation - Google Patents

Cannabinoid-based formulation

Info

Publication number
GB202306990D0
GB202306990D0 GBGB2306990.9A GB202306990A GB202306990D0 GB 202306990 D0 GB202306990 D0 GB 202306990D0 GB 202306990 A GB202306990 A GB 202306990A GB 202306990 D0 GB202306990 D0 GB 202306990D0
Authority
GB
United Kingdom
Prior art keywords
cannabinoid
based formulation
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2306990.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MRX Medical Ltd
Original Assignee
MRX Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MRX Medical Ltd filed Critical MRX Medical Ltd
Priority to GBGB2306990.9A priority Critical patent/GB202306990D0/en
Publication of GB202306990D0 publication Critical patent/GB202306990D0/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
GBGB2306990.9A 2023-05-11 2023-05-11 Cannabinoid-based formulation Ceased GB202306990D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB2306990.9A GB202306990D0 (en) 2023-05-11 2023-05-11 Cannabinoid-based formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2306990.9A GB202306990D0 (en) 2023-05-11 2023-05-11 Cannabinoid-based formulation

Publications (1)

Publication Number Publication Date
GB202306990D0 true GB202306990D0 (en) 2023-06-28

Family

ID=86872380

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2306990.9A Ceased GB202306990D0 (en) 2023-05-11 2023-05-11 Cannabinoid-based formulation

Country Status (1)

Country Link
GB (1) GB202306990D0 (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1990, MACK PUB. CO.

Similar Documents

Publication Publication Date Title
IL319149A (en) Upadacitinib formulation
GB202007546D0 (en) Formulation
IL307849A (en) Sotorasib formulation
GB202318884D0 (en) Formulation
GB202316857D0 (en) Cannabinoid-based formulation
GB202312814D0 (en) Formulation
GB202312220D0 (en) Formulation
GB202311622D0 (en) Formulation
GB202311439D0 (en) Formulation
IL317857A (en) Orellanine formulation
GB202308224D0 (en) Formulation
GB202306995D0 (en) Cannabinoid-based formulation
GB202306990D0 (en) Cannabinoid-based formulation
GB202307002D0 (en) Cannabinoid-based formulation
GB202307003D0 (en) Cannabinoid-based formulation
GB202303663D0 (en) Aerosolisable formulation
GB202218160D0 (en) Formulation
GB202217857D0 (en) Formulation
GB202217267D0 (en) Aerosolisable formulation
GB202217148D0 (en) Formulation
GB202216335D0 (en) Formulation
GB202213663D0 (en) Aerosolisable formulation
GB202211203D0 (en) Formulation
GB202209298D0 (en) Aerosolisable formulation
GB202211231D0 (en) Novel formulation

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)